OnabotulinumtoxinA for Trigeminal Neuralgia
Key facts
- Where
- Stanford, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Meredith BaradStanford, United StatesContact: Meredith Study TeamTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Stanford University
- Trial code
- NCT06216886
- Record updated
- 22 January 2026
- Original description
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.Read full original descriptionShow less
Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
Inclusion: Men and women age 18 or older; Judged to be of legal competence; Sufficient knowledge of written and spoken English; Capable of attending regular in-person visits; Have failed/not a candidate/do not want surgery; Inadequate response to medication - at least 2 trials; Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1; Patients with frequency > 10 attacks per week; Stable dose of medications in the last 2 weeks.
Exclusion: Neuromuscular disease; Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2); Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C); On aminoglyocosides; Not currently enrolled in any other studies.